1.Bouvier-Colle MH, Flahaut A, Messiah A, Jougla E, Hatton F. Sudden infant death and immunization: an extensive epidemiological approach to the problem in France--winter 1986. Int J Epidemiol [Internet]. 1989 Mar [cited 2012 Jun 27];18(1):121–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2722354
1.Benhamou D, Lienhart A, Auroy Y, Péquignot F, Jougla E. Accidents by ABO incompatibility and other main complications related to blood transfusion in surgical patients: data from the French national survey on anaesthesia-related deaths. Transfus Clin Biol. 2005 Nov;12(5):389–90.
Lewden C, Salmon D, Morlat P, Bévilacqua S, Jougla E, Bonnet F, et al. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol. 2005 Feb;34(1):121–30.
Salmon-Ceron D, Lewden C, Morlat P, Bévilacqua S, Jougla E, Bonnet F, et al. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol. 2005 Jun;42(6):799–805.
1.Bonnet F, Lewden C, May T, Heripret L, Jougla E, Bevilacqua S, et al. Opportunistic infections as causes of death in HIV-infected patients in the HAART era in France. Scand J Infect Dis. 2005;37(6–7):482–7.
Carbonneil C, Donkova-Petrini V, Aouba A, Weiss L. Defective dendritic cell function in HIV-infected patients receiving effective highly active antiretroviral therapy: neutralization of IL-10 production and depletion of CD4+CD25+ T cells restore high levels of HIV-specific CD4+ T cell responses induced by dendritic cells generated in the presence of IFN-alpha. J Immunol. 2004 Jun 15;172(12):7832–40.
1.Bouvier AM, Remontet L, Jougla E, Launoy G, Grosclaude P, Buémi A, et al. Incidence of gastrointestinal cancers in France. Gastroenterol Clin Biol. 2004 Oct;28(10 Pt 1):877–81.
1.Peng J, Ménégoz F, Lesec’h JM, Remontet L, Grosclaude P, Buémi A, et al. [Larynx cancer in France: descriptive epidemiology and incidence estimation]. Bull Cancer. 2004 Apr;91(4):363–8.
1.Bonnet F, Lewden C, May T, Heripret L, Jougla E, Bevilacqua S, et al. Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy. Cancer. 2004 Jul 15;101(2):317–24.
1.Lienhart A, Auroy Y, Péquignot F, Benhamou D, Warszawski J, Bovet M, et al. [Preliminary results from the SFAR-iNSERM inquiry on anaesthesia-related deaths in France: mortality rates have fallen ten-fold over the past two decades]. Bull Acad Natl Med. 2004;188(8):1429–37; discussion 1437-1441.
Jougla E, Rican S, Péquignot F, Le Toullec A. [Socio-economic differences in mortality]. Rev Prat. 2004 Dec 31;54(20):2228–32.
1.Jougla E, Ducimetière P, Bouvier-Colle MH, Hatton F. [Relation between the level of the development of the care system and the level of “preventable” mortality according to department in France]. Rev Epidemiol Sante Publique [Internet]. 1987 [cited 2012 Jun 27];35(5):365–77. Available from: http://www.ncbi.nlm.nih.gov/pubmed/3432706
Nelson DE, Jarman DW, Rehm J, Greenfield TK, Rey G, Kerr WC, et al. Alcohol-attributable cancer deaths and years of potential life lost in the United States. Am J Public Health. 2013 Apr;103(4):641–8.
1.Hoffmann R, Plug I, Khoshaba B, McKee M, Mackenbach JP, AMIEHS working group. Amenable mortality revisited: the AMIEHS study. Gac Sanit. 2013 Jun;27(3):199–206.
1.Menvielle G, Rey G, Jougla E, Luce D. Diverging trends in educational inequalities in cancer mortality between men and women in the 2000s in France. BMC Public Health. 2013 Sep 10;13(1):823.
1.Hoffmann R, Plug I, McKee M, Khoshaba B, Westerling R, Looman C, et al. Innovations in health care and mortality trends from five cancers in seven European countries between 1970 and 2005. Int J Public Health. 2013 Aug 29;
1.Hoffmann R, Plug I, McKee M, Khoshaba B, Westerling R, Looman C, et al. Innovations in medical care and mortality trends from four circulatory diseases between 1970 and 2005. Eur J Public Health. 2013 Oct;23(5):852–7.
1.Marijon E, Tafflet M, Antero-Jacquemin J, El Helou N, Berthelot G, Celermajer DS, et al. Mortality of French participants in the Tour de France (1947-2012). Eur Heart J. 2013 Oct;34(40):3145–50.
1.Rafnsson SB, Bhopal RS, Agyemang C, Fagot-Campagna A, Harding S, Hammar N, et al. Sizable variations in circulatory disease mortality by region and country of birth in six European countries. Eur J Public Health. 2013 Aug;23(4):594–605.
1.Ghosn W, Kassie D, Jougla E, Rican S, Rey G. Spatial interactions between urban areas and cause-specific mortality differentials in France. Health Place. 2013 Nov;24:234–41.
1.Ghosn W, Kassié D, Jougla E, Salem G, Rey G, Rican S. Trends in geographic mortality inequalities and their association with population changes in France, 1975-2006. Eur J Public Health. 2013 Oct;23(5):834–40.
Mackenbach JP, Hoffmann R, Khoshaba B, Plug I, Rey G, Westerling R, et al. Using “amenable mortality” as indicator of healthcare effectiveness in international comparisons: results of a validation study. J Epidemiol Community Health. 2013 Feb;67(2):139–46.
1.Ecoffey C, Auroy Y, Pequignot F, Jougla E, Clergue F, Laxenaire MC, et al. A French survey of paediatric airway management use in tonsillectomy and appendicectomy. Paediatr Anaesth. 2003 Sep;13(7):584–8.
Lewden C, Bonnet F, Bevilacqua S, Heripret L, May T, Morlat P, et al. [Causes of death in HIV-infected French drug users, 1995-2000]. Ann Med Interne (Paris). 2002 Nov;153(7 Suppl):2S4-10.
1.Clergue F, Auroy Y, Pequignot F, Jougla E, Lienhart A, Laxenaire MC. Evolution of the anaesthetic workload--the French experience. Best Pract Res Clin Anaesthesiol. 2002 Sep;16(3):459–73.
1.Karimi M, Rey G, Latouche A. A Joint modelling of socio-professional trajectories and cause-specific mortality. Computational Statistics & Data Analysis [Internet]. 2018 Mar 1 [cited 2018 May 14];119:39–54. Available from: http://www.sciencedirect.com/science/article/pii/S0167947317302207
1.Rey G, Bounebache K, Rondet C. Causes of deaths data, linkages and big data perspectives. J Forensic Leg Med. 2018 Jul;57:37–40.
1.Chazal T, Lhote R, Rey G, Haroche J, Eb M, Amoura Z, et al. Giant-cell arteritis-related mortality in France: A multiple-cause-of-death analysis. Autoimmun Rev. 2018 Dec;17(12):1219–24.
1.Aouba A, Gonzalez Chiappe S, Eb M, Delmas C, de Boysson H, Bienvenu B, et al. Mortality causes and trends associated with giant cell arteritis: analysis of the French national death certificate database (1980-2011). Rheumatology (Oxford). 2018 Jun 1;57(6):1047–55.
1.Chaignot C, Zureik M, Rey G, Dray-Spira R, Coste J, Weill A. Risk of hospitalisation and death related to baclofen for alcohol use disorders: Comparison with nalmefene, acamprosate, and naltrexone in a cohort study of 165 334 patients between 2009 and 2015 in France. Pharmacoepidemiol Drug Saf. 2018 Nov;27(11):1239–48.